Spain's Council of Ministers approved Royal Decree 903/2025 on October 7, 2025. Nine months later, in July 2026, the first standardized cannabis preparations entered the national registry. For a Canadian Licensed Producer, those nine months show how slowly Spain's buyer base is forming.
Exporting cannabis to Spain in 2026 means supplying a pharmaceutical laboratory. Under the decree, patients receive only hospital-compounded preparations made from standardized cannabis preparations registered with the AEMPS, Spain's medicines agency. Dried flower is never dispensed. Canadian flower enters Spain as starting material, shipped under a Health Canada export permit matched to a Spanish import authorisation.
What Royal Decree 903/2025 allows in 2026
The decree governs how cannabis-based typified magistral formulas are prescribed, prepared, dispensed and monitored. Every formula must start from a standardized preparation listed in the AEMPS Register of Standardized Cannabis Preparations, with a defined THC and/or CBD composition. Preparation happens only in authorised hospital pharmacy services. Community pharmacies are excluded, and so is home use.
Prescribing is limited to specialist physicians, and only for the four indications set out in the framework: spasticity in multiple sclerosis, severe refractory epilepsy, chemotherapy-induced nausea and vomiting, and refractory chronic pain. In each case, conventional authorised medicines must have failed first.
The implementation timeline
- October 7, 2025: the Council of Ministers approves the decree.
- October 9, 2025: the decree is published in the Boletín Oficial del Estado.
- January 19, 2026: the AEMPS publishes the procedure for registering standardized preparations.
- January 2026: monograph FN/2026/FMT/043 enters the National Formulary, defining an oil-based oral solution with THC and/or CBD.
- July 13, 2026: Curaleaf announces the first two registrations, CAN-1 and CAN-2, made at its Spanish subsidiary.
The registration procedure opened on January 19. The first approvals arrived about six months later. That is how long it took a company already holding a Spanish licence and an EU-GMP facility, so expect the buyer pool to stay small through 2026.
Where Canadian flower fits in Spain's supply chain
Spain's model puts a manufacturer between you and the hospital. The chain runs in four steps:
- A Canadian LP exports dried flower to an authorised Spanish laboratory.
- The laboratory extracts and standardizes it under EU-GMP, then registers the preparation with the AEMPS.
- Hospital pharmacy services compound the registered preparation into the oral solution described in the monograph.
- A specialist prescribes it, and the patient collects it from the hospital.
Compare that with Germany, where many Canadian LPs started their EU export work. The two markets ask for different products.
| Factor | Spain | Germany |
|---|---|---|
| Form reaching patients | Oil-based oral solution only | Dried flower and extracts |
| Dispensing point | Hospital pharmacy services | Community pharmacies |
| Medicines regulator | AEMPS | BfArM |
| Your direct customer | Pharmaceutical laboratory | Licensed importer or distributor |
| What you sell | Starting material for extraction | Finished, packaged flower |
This changes what a buyer pays for. A Spanish laboratory turns your flower into a preparation with a registered cannabinoid composition, so batch-to-batch potency consistency matters far more to them than bud structure or bag appeal. If you want to compare Spain against other European routes, our EU cannabis import comparison by country lays out the alternatives.
Spain is not a flower market. An LP that pitches retail-ready premium buds to Spanish buyers is selling into a channel the decree never created.
The Spain starting-material dossier: 5 documents
A Spanish laboratory has to defend its supply chain in its own registration file. The decree's registry expects proper manufacturing, distribution, traceability and supply-chain auditing standards, and that scrutiny flows straight back to you. Build these five documents before the first call.
1. The permit pair
Spain is a party to the Single Convention on Narcotic Drugs, so every shipment needs an AEMPS import authorisation and a matching Health Canada export permit issued under the Cannabis Act. Our guides to the Health Canada export permit process and to narcotics import permits cover the sequencing. Quantities also sit inside Spain's annual estimates filed with the INCB.
2. Cultivation records under GACP
The laboratory treats your flower as an herbal starting material. Expect questions mapped to GACP: cultivar identity, growing inputs, harvest records and pest control logs.
3. Post-harvest controls
Drying, trimming and packaging sit between cultivation and the lab's GMP boundary. Their Qualified Person will ask how those steps are controlled and whether an EU authority has inspected them. Our breakdown of EU-GMP certification for a Canadian facility explains what that inspection involves.
4. Batch COAs with a consistency history
One certificate isn't enough. Send several consecutive batch COAs from an ISO/IEC 17025 accredited lab, showing cannabinoid content, contaminants and microbial results. This is where qualification usually slows down. A single strong batch says nothing about the variance the lab has to standardize away.
5. Traceability and a quality agreement
Seed-to-shipment batch records let the lab trace any registered lot back to your rooms. A signed quality agreement sets out who handles deviations, complaints and change notifications.
The permit pair gets a shipment moving. The COA history is what wins the supply contract.
How to approach Spanish buyers in 2026
Start with the laboratories. Hospitals buy registered preparations, and laboratories buy the flower that goes into them. The realistic targets are pharmaceutical manufacturers that already hold AEMPS authorisation for cannabis derivatives and run EU-GMP sites, plus groups preparing their own registration files.
Expect a supplier qualification audit before any purchase order. Plan for document review, a possible site visit and a trial lot tested on arrival. Pricing talks will likely anchor on cannabinoid yield per kilogram rather than bud grade, so prepare your numbers on that basis.
Keep volume expectations honest. Four indications and hospital-only dispensing mean Spain will start small. Treat it as a second EU channel next to Germany, and use the qualification work to strengthen your file for other pharmaceutical buyers. The Portugal processing hub route is worth weighing at the same time.
AlphaLeaf is a Health Canada Licensed Producer based in Montreal, growing indoor flower from refined genetics and verifying every batch through ISO/IEC 17025 testing. We hold export authorisation under the Cannabis Act and keep full batch traceability records, the documentation an EU pharmaceutical laboratory needs before it qualifies a Canadian starting-material supplier.
Evaluating Spain as your next EU channel? Talk to our export team about specifications and batch history. We'll share recent COAs on request.
Frequently Asked Questions
Can dried cannabis flower be dispensed to patients in Spain?
No. Under Royal Decree 903/2025, patients receive only typified magistral formulas compounded in hospital pharmacy services from AEMPS-registered standardized preparations. The January 2026 monograph defines an oil-based oral solution with THC and/or CBD. Flower can still enter Spain as starting material for an authorised manufacturer.
Who can prescribe medical cannabis in Spain?
Only specialist physicians, for the four indications in the framework: spasticity in multiple sclerosis, severe refractory epilepsy, chemotherapy-induced nausea and vomiting, and refractory chronic pain. Conventional authorised medicines must have failed first, and dispensing happens only through hospital pharmacy services.
Can a Canadian Licensed Producer export cannabis to Spain?
Yes, when the buyer holds an AEMPS import authorisation and the shipment moves under a matching Health Canada export permit. In practice, the buyer is a pharmaceutical laboratory that extracts the flower and registers a standardized preparation with the AEMPS.
What is the AEMPS Register of Standardized Cannabis Preparations?
It is the public registry created by Royal Decree 903/2025. Only registered preparations can be used to make cannabis magistral formulas in Spain. The AEMPS published the registration procedure on January 19, 2026, and the first two registrations, CAN-1 and CAN-2, were announced in July 2026.
What documents should a Canadian LP prepare for a Spanish buyer?
Prepare five things: the export and import permit pair, GACP-mapped cultivation records, evidence of post-harvest controls, several consecutive ISO/IEC 17025 batch COAs showing cannabinoid consistency, and full traceability records backed by a quality agreement.
